vTv Therapeutics Q3 net loss widens to $8.7 mln
vTv Therapeutics reported a Q3 net loss of $8.7 million, attributed to increased R&D expenses for cadisegliatin development. The company completed an $80 million private placement to support its Phase 3 CATT1 trial. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $35.50, representing a 31.7% upside from its recent closing price of $24.24.
)
Overview
- vTv’s Q3 net loss widens to $8.7 mln, driven by higher R&D expenses
- Company completes $80 mln private placement to fund Phase 3 CATT1 trial
Result Drivers
- PRIVATE PLACEMENT - $80 mln private placement strengthens balance sheet and supports Phase 3 CATT1 trial
- R&D EXPENSES - Increased R&D spending reflects higher investment in cadisegliatin development
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 $10.70
Operatin mln
g
Expenses
Q3 -$10.70
Operatin mln
g Income
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 2 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for vTv Therapeutics Inc is $35.50, about 31.7% above its November 5 closing price of $24.24
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
